Core Viewpoint - Weigao Blood Products (603014) experienced a decline of 1.55% in stock price, with a trading volume turnover rate of 34.24% and a total transaction amount of 559 million yuan, indicating significant trading activity and potential investor concern [2]. Trading Activity - The stock was listed on the Shanghai Stock Exchange due to its high turnover rate, with a net selling amount of 18.46 million yuan from brokerage seats [2]. - The top five brokerage seats accounted for a total transaction amount of 212 million yuan, with buying transactions amounting to 96.58 million yuan and selling transactions totaling 115 million yuan, resulting in a net selling of 18.46 million yuan [2]. - The largest buying brokerage was GF Securities, which purchased 31.49 million yuan, while the largest selling brokerage was Huaxin Securities, which sold 34.16 million yuan [2]. Fund Flow - The stock saw a net inflow of 50.76 million yuan from major funds, with a significant inflow of 11.35 million yuan from large orders and 39.41 million yuan from regular orders. Over the past five days, the net inflow of major funds reached 171 million yuan [2]. Financial Performance - According to the semi-annual report released on August 28, the company achieved a revenue of 1.765 billion yuan in the first half of the year, representing a year-on-year growth of 8.52%. The net profit for the same period was 220 million yuan, reflecting a year-on-year increase of 10.11% [2].
威高血净9月3日龙虎榜数据